Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

NSE:MARKSANS

Marksans Pharma Limited

Last Close

164.85

18/05 07:00

Market Cap

65.05B

Beta: 1.23

Volume Today

415.13K

Avg: 2.09M

PE Ratio

22.85

PFCF: -

Dividend Yield

0.33%

Payout:0%

Financials Not Available